Market Overview

UPDATE: Rodman & Renshaw Maintains Outperform on Cytokinetics; $2 PT


Rodman & Renshaw reiterated an Outperform rating on Cytokinetics (NASDAQ: CYTK) and a target price of $2.

Rodman & Renshaw wrote, “We expect management to provide further details on omecamtiv mecarbil's planned Phase II trials with oral formulations. Management announced last week that the company has selected oral formulations of omecamtiv mecarbil in order to advance the compound into Phase II clinical trials. The selection of oral compounds was based on data reviewed from the recently completed Phase I clinical trial, which was a randomized, open-label study designed to establish the bioavailability of oral formulations of omecamtiv mecarbil in healthy volunteers.”

Cytokinetics closed at $0.73 on Monday.

Posted-In: Rodman & RenshawAnalyst Color Reiteration Analyst Ratings


Related Articles (CYTK)

View Comments and Join the Discussion!

Latest Ratings

CBBMorgan StanleyUpgrades10.0
GDCredit SuisseDowngrades184.0
GEOJP MorganDowngrades26.0
TRUERBC CapitalDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: Rodman & Redshaw Reiterates Outperform on Alynlam Pharmaceuticals; $22 PT

ForexLive Asia Wrap Up